|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-7-8
|
|
pubmed:abstractText |
Thiazolidinediones (TZDs) have been implemented into clinical practice for the treatment of type 2 diabetes mellitus as specific peroxisome proliferator-activated receptor (PPAR)-gamma ligands. Moreover, recent evidence has suggested that TZDs might have favorable effects in the treatment of a variety of tumors as differentiation-inducing agents. Adrenocortical carcinoma (ACC) is a rare tumor entity with poor prognosis due to its highly malignant phenotype and lack of effective treatment options.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-chloro-5-nitrobenzanilide,
http://linkedlifedata.com/resource/pubmed/chemical/Anilides,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin E,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor II,
http://linkedlifedata.com/resource/pubmed/chemical/PPAR gamma,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Melanocortin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones,
http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3886-96
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15886257-Adrenal Cortex Neoplasms,
pubmed-meshheading:15886257-Adult,
pubmed-meshheading:15886257-Aged,
pubmed-meshheading:15886257-Anilides,
pubmed-meshheading:15886257-Apoptosis,
pubmed-meshheading:15886257-Cell Differentiation,
pubmed-meshheading:15886257-Cell Line, Tumor,
pubmed-meshheading:15886257-Cell Proliferation,
pubmed-meshheading:15886257-Cyclin E,
pubmed-meshheading:15886257-Dose-Response Relationship, Drug,
pubmed-meshheading:15886257-Female,
pubmed-meshheading:15886257-Humans,
pubmed-meshheading:15886257-Insulin-Like Growth Factor II,
pubmed-meshheading:15886257-Male,
pubmed-meshheading:15886257-Middle Aged,
pubmed-meshheading:15886257-PPAR gamma,
pubmed-meshheading:15886257-Promoter Regions, Genetic,
pubmed-meshheading:15886257-RNA, Messenger,
pubmed-meshheading:15886257-Receptor, Melanocortin, Type 2,
pubmed-meshheading:15886257-Thiazolidinediones
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
|
|
pubmed:affiliation |
Division of Endocrinology and Diabetes, Department of Internal Medicine II, University of Freiburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
